Dalargin

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 462018

CAS#: 81733-79-1

Description: Dalargin is a endogenous opioid peptide leucine-encephalin. It exhibits a pronounced cytoprotective and regeneratory action and may take an important place in treating the internal organ diseases.


Chemical Structure

img
Dalargin
CAS# 81733-79-1

Theoretical Analysis

MedKoo Cat#: 462018
Name: Dalargin
CAS#: 81733-79-1
Chemical Formula: C35H51N9O8
Exact Mass: 725.3861
Molecular Weight: 725.848
Elemental Analysis: C, 57.92; H, 7.08; N, 17.37; O, 17.63

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Dalargin; Tageflar; BRN 4287455; Tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine

IUPAC/Chemical Name: L-Arginine, N(sup 2)-(N-(N-(N-(L-tyrosyl-D-alanyl)glycyl)-L-phenylalanyl)-L-leucyl)-

InChi Key: GDPHPXYFLPDZGH-XBTMSFKCSA-N

InChi Code: InChI=1S/C35H51N9O8/c1-20(2)16-27(32(49)43-26(34(51)52)10-7-15-39-35(37)38)44-33(50)28(18-22-8-5-4-6-9-22)42-29(46)19-40-30(47)21(3)41-31(48)25(36)17-23-11-13-24(45)14-12-23/h4-6,8-9,11-14,20-21,25-28,45H,7,10,15-19,36H2,1-3H3,(H,40,47)(H,41,48)(H,42,46)(H,43,49)(H,44,50)(H,51,52)(H4,37,38,39)/t21-,25+,26+,27+,28+/m1/s1

SMILES Code: N=C(N)NCCC[C@@H](C(O)=O)NC([C@H](CC(C)C)NC([C@H](CC1=CC=CC=C1)NC(CNC([C@@H](C)NC([C@H](CC2=CC=C(O)C=C2)N)=O)=O)=O)=O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 725.848 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Activity profiles of dalargin and its analogues in μ-, δ- and κ-opioid receptor selective bioassays
Nevena Pencheva, Jan Pospišek, Linda Hauzerova, Tomislav Barth, Peter Milanov Br J Pharmacol. 1999 Oct; 128(3): 569–576. doi: 10.1038/sj.bjp.0702825 PMCID: PMC1571668

2: Improvement of Peptide Affinity and Stability by Complexing to Cyclodextrin-Grafted Ammonium Chitosan Andrea Cesari, Alessandra Recchimurzo, Angela Fabiano, Federica Balzano, Nicolò Rossi, Chiara Migone, Gloria Uccello-Barretta, Ylenia Zambito, Anna Maria Piras Polymers (Basel) 2020 Feb; 12(2): 474. Published online 2020 Feb 19. doi: 10.3390/polym12020474 PMCID: PMC7077720

3: Influence of Chronobiology on the Nanoparticle-Mediated Drug Uptake into the Brain
Jörg Kreuter Pharmaceutics. 2015 Mar; 7(1): 3–9. Published online 2015 Feb 3. doi: 10.3390/pharmaceutics7010003 PMCID: PMC4381197

4: The Bactericidal Activity of Temporin Analogues Against Methicillin Resistant Staphylococcus aureus Anna Golda, Paulina Kosikowska-Adamus, Aleksandra Kret, Olena Babyak, Kinga Wójcik, Ewelina Dobosz, Jan Potempa, Adam Lesner, Joanna Koziel Int J Mol Sci. 2019 Oct; 20(19): 4761. Published online 2019 Sep 25. doi: 10.3390/ijms20194761 PMCID: PMC6801822

5: Approaches to CNS Drug Delivery with a Focus on Transporter-Mediated Transcytosis Rana Abdul Razzak, Gordon J. Florence, Frank J. Gunn-Moore Int J Mol Sci. 2019 Jun; 20(12): 3108. Published online 2019 Jun 25. doi: 10.3390/ijms20123108 PMCID: PMC6627589

6: Multifunctional Polymeric Nanoplatforms for Brain Diseases Diagnosis, Therapy and Theranostics Shahryar Shakeri, Milad Ashrafizadeh, Ali Zarrabi, Rasoul Roghanian, Elham Ghasemipour Afshar, Abbas Pardakhty, Reza Mohammadinejad, Anuj Kumar, Vijay Kumar Thakur Biomedicines. 2020 Jan; 8(1): 13. Published online 2020 Jan 13. doi: 10.3390/biomedicines8010013 PMCID: PMC7168063

7: Prospects for Creation of Cardioprotective and Antiarrhythmic Drugs Based on Opioid Receptor Agonists Leonid N Maslov, Igor Khaliulin, Peter R. Oeltgen, Natalia V. Naryzhnaya, Jian‐Ming Pei, Stephen A. Brown, Yury B. Lishmanov, James M. Downey Med Res Rev. 2016 Sep; 36(5): 871–923. Published online 2016 May 16. doi: 10.1002/med.21395 PMCID: PMC5082499

8: Polymeric Nanoparticles for the Treatment of Malignant Gliomas Basant Salah Mahmoud, Ali Hamod AlAmri, Christopher McConville Cancers (Basel) 2020 Jan; 12(1): 175. Published online 2020 Jan 10. doi: 10.3390/cancers12010175 PMCID: PMC7017235

9: Agile Delivery of Protein Therapeutics to CNS Xiang Yi, Devika S. Manickam, Anna Brynskikh, Alexander V. Kabanov J Control Release. Author manuscript; available in PMC 2015 Sep 28.Published in final edited form as: J Control Release. 2014 Sep 28; 0: 637–663. Published online 2014 Jun 21. doi: 10.1016/j.jconrel.2014.06.017 PMCID: PMC4142106

10: Enabling nanomaterial, nanofabrication and cellular technologies for nanoneuromedicines Surya K. Mallapragada, Timothy M. Brenza, JoEllyn M. McMillan, Balaji Narasimhan, Donald S. Sakaguchi, Anup D. Sharma, Svitlana Zbarska, Howard E. Gendelman Nanomedicine. Author manuscript; available in PMC 2016 Apr 1.Published in final edited form as: Nanomedicine. 2015 Apr; 11(3): 715–729. Published online 2015 Jan 31. doi: 10.1016/j.nano.2014.12.013 PMCID: PMC4628726